AbbVie Wore 'Blinders' On AndroGel's Clot Risk, Jury Told
AbbVie Inc. had "blinders" on when it came to AndroGel's risk of blood clots, counsel for a man who had a deep vein thrombosis while taking the testosterone replacement therapy drug...To view the full article, register now.
Already a subscriber? Click here to view full article